Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Giant cell myocarditis (GCM) is a rare disorder in which survival beyond 1 year without heart transplantation is uncommon. Long-term follow-up data on those with such survival are lacking. Twenty-six patients with biopsy-proved GCM who survived for > 1 year without heart transplantation were identified from a multicenter GCM registry. The incidenceof death, transplantation, ventricular assist device placement, and histologically proved disease recurrence was ascertained retrospectively. The rates of recurrent heart failure, ventricular arrhythmias, renal failure, and infectious complications were calculated. The mean age of the cohort was 54.6 ± 13.9 years (65% women). The mean follow-up duration was 5.5 years starting 1 year after diagnosis. There were 3 deaths (12%), 5heart transplantations (19%), and 1 ventricular assist device placement (4%). Three histologically confirmed recurrences of GCM (12%) occurred between 1.5 and 8 years after diagnosis. Thirteen of 26 patients experienced a total of 30 heart failure episodes ≥1 year after initial diagnosis. There were 23 episodes of elevated creatinine in 12 patients, 41 infectiousevents in 13 patients, and 19 episodes of ventricular arrhythmias in 6 patients with a total of 144 years of follow-up. Starting 1 year after GCM diagnosis, the combined rate of death, transplantation, ventricular assist device placement, and GCM recurrence was 47% at 5 years. In conclusion, the risk for GCM recurrence continues to ≥ 8 years after diagnosis.
Joseph J. Maleszewski, MD a,b,*, Victor M. Orellana, MDc, David O. Hodge, MSd, Uwe Kuhl, MDe, Heinz-Peter Schultheiss, MDe, and Leslie T. Cooper, MDbDivisions of aAnatomic Pathology and bCardiovascular Diseases and dDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; cDepartment of Medicine, Alpert Medical School, Brown University, Providence, Rhode Island; and eDepartment of Cardiology, Charite Hospital, Benjamin Franklin Campus, Berlin, GermanyAm J Cardiol. 2015 Mar 24. pii: S0002-9149(15)00978-9. doi: 10.1016/j.amjcard.2015.03.023.
Presented by Alida LP Caforio, MD, PhD, FESC, Cardiology, Dept of Cardiological Thoracic and Vascular Sciences, University of Padova, Italy. firstname.lastname@example.org
© 2016 European Society of Cardiology. All rights reserved